GLP-1 Market
LLY $1179.27 ▲ +0.8% NVO $38.64 ▲ +1.2% PFE $28.28 ▲ +1.7% VKTX $28.51 ▲ +2.8% KLRA $11.61 ▲ +16.1% GPCR $25.54 ▼ -0.5% RHHBY $54.09 ▲ +1.3%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

relacorilant

Company
Corcept Therapeutics
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
3 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

3 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 10, 2026

Find a Clinical Trial Near Me

See recruiting studies for relacorilant and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT05726292

    A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

    Not yet reported University of Chicago 90 participants Est. completion 2028-04-01 4 sites Stand-alone
    Other conditions: Prostate Cancer, Prostate Adenocarcinoma
    View official trial listing →
  • Recruiting NCT NCT06906341

    Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

    Not yet reported Corcept Therapeutics 270 participants Est. completion 2026-12 49 sites Stand-alone
    Other conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer
    View official trial listing →
  • Recruiting NCT NCT07259317

    Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

    Not yet reported Corcept Therapeutics 80 participants Est. completion 2027-09 20 sites Stand-alone
    Other conditions: Adenocarcinoma, Carcinoma, Pancreatic Ductal
    View official trial listing →
  • Completed NCT NCT02762981

    Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors

    Not yet reported, Not yet reported Corcept Therapeutics 85 participants Est. completion 2020-09-12 4 sites Stand-alone
    Other conditions: Solid Tumors
    View official trial listing →
  • Completed NCT NCT02804750

    Study to Evaluate CORT125134 in Participants With Cushing's Syndrome

    Not yet reported Corcept Therapeutics 35 participants Est. completion 2018-09 25 sites Stand-alone
    Other conditions: Cushing's Syndrome
    View official trial listing →
  • Completed NCT NCT03067376

    A Study Designed to See How [14C]-CORT125134 is Taken up, Broken Down and Removed From the Body

    Not yet reported Corcept Therapeutics 9 participants Est. completion 2016-09 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT03442621

    Relacorilant Food Effect Study in Healthy Subjects

    Not yet reported Corcept Therapeutics 30 participants Est. completion 2018-03-09 1 site Stand-alone
    Other conditions: Healthy, Food-drug Interaction
    View official trial listing →
  • Completed NCT NCT03457597

    Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s

    Not yet reported Corcept Therapeutics 27 participants Est. completion 2018-04-28 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT03508635

    CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)

    Not yet reported Corcept Therapeutics 130 participants Est. completion 2015-12 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT03512548

    Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its Metabolites

    Not yet reported Corcept Therapeutics 52 participants Est. completion 2019-08-23 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT03540836

    A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsule Variants

    Not yet reported Corcept Therapeutics 30 participants Est. completion 2018-07-25 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Active, not recruiting NCT NCT03604198

    Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

    Not yet reported Corcept Therapeutics 125 participants Est. completion 2026-12 48 sites Stand-alone
    Other conditions: Cushing Syndrome
    View official trial listing →
  • Completed NCT NCT03674814

    Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer

    Not yet reported University of Chicago 42 participants Est. completion 2024-06-10 1 site Stand-alone
    Other conditions: Prostate Cancer
    View official trial listing →
  • Completed NCT NCT03697109

    A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome

    Not yet reported Corcept Therapeutics 152 participants Est. completion 2024-04-15 64 sites Stand-alone
    Other conditions: Cushing Syndrome
    View official trial listing →
  • Completed NCT NCT03776812

    Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    Not yet reported Corcept Therapeutics 178 participants Est. completion 2023-07-12 24 sites Stand-alone
    Other conditions: Recurrent Ovarian Cancer, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma
    View official trial listing →
  • Completed NCT NCT04308590

    A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas

    Not yet reported Corcept Therapeutics 137 participants Est. completion 2024-09-19 45 sites Stand-alone
    Other conditions: Hypercortisolism
    View official trial listing →
  • Terminated NCT NCT04329949

    Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

    Not yet reported Corcept Therapeutics 43 participants Est. completion 2022-03-25 18 sites Stand-alone
    Other conditions: Metastatic Pancreatic Ductal Adenocarcinoma
    View official trial listing →
  • Completed NCT NCT04373265

    Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)

    Not yet reported Corcept Therapeutics 15 participants Est. completion 2024-01-12 6 sites Stand-alone
    Other conditions: Adrenocortical Carcinoma
    View official trial listing →
  • Completed NCT NCT04795479

    T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers

    Not yet reported Corcept Therapeutics 36 participants Est. completion 2021-07-13 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Active, not recruiting NCT NCT05257408

    Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

    Not yet reported Corcept Therapeutics 381 participants Est. completion 2026-12 116 sites Stand-alone
    Other conditions: Ovarian Neoplasm, Fallopian Tube Neoplasms, Peritoneal Neoplasms
    View official trial listing →
  • Completed NCT NCT05347979

    Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants

    Not yet reported Corcept Therapeutics 30 participants Est. completion 2022-07-19 1 site Stand-alone
    Other conditions: Cushing Syndrome, Neoplasms
    View official trial listing →
  • Completed NCT NCT06094712

    A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male Subjects

    Not yet reported Corcept Therapeutics 8 participants Est. completion 2016-04-27 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT06094725

    A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant

    Not yet reported Corcept Therapeutics 30 participants Est. completion 2020-12-14 2 sites Stand-alone
    Other conditions: Hepatic Impairment
    View official trial listing →
  • Completed NCT NCT06094738

    A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects

    Not yet reported Corcept Therapeutics 30 participants Est. completion 2020-11-16 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT06094790

    A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy Subjects

    Not yet reported Corcept Therapeutics 32 participants Est. completion 2017-11-15 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Not yet recruiting NCT NCT07763496

    Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical Cancer

    Not yet reported ARCAGY/ GINECO GROUP 63 participants Est. completion 2030-12 2 sites Stand-alone
    Other conditions: Recurrent or Metastatic Cervical Cancer
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: relacorilant, CORT125134

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.